Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ASCENDIS PHARMA A/S

(ASND)
  Report
Delayed Nasdaq  -  04:00:01 2023-02-07 pm EST
116.35 USD   +1.93%
08:01aAscendis Pharma Announces Full Year 2022 Financial Results and Business Update Conference Call on February 16
AQ
01/18Tech Stocks Lead European Equities Modestly Higher in Wednesday Trading
MT
01/17Pharma Stocks Lead European Equities Higher in Tuesday Trading
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Evolution of the average Target Price on ASCENDIS PHARMA A/S
Target Price consensus revisions : last 18 months
Recommendations (Chart) ASCENDIS PHARMA A/S
Analyst Recommendations on ASCENDIS PHARMA A/S
01/17SVB Securities Adjusts Price Target on Ascendis Pharma to $163 From $148, Maintains Outper..
MT
01/03Wells Fargo Boosts Price Target on Ascendis Pharma to $177 From $169, Keeps Overweight Rat..
MT
2022Morgan Stanley Adjusts Price Target on Ascendis Pharma to $148 From $146, Maintains Overwe..
MT
2022Wedbush Raises Price Target on Ascendis Pharma to $164 From $151, Keeps Outperform Rating
MT
2022Wells Fargo Adjusts Price Target on Ascendis Pharma to $169 From $172, Maintains Overweigh..
MT
2022Citigroup Adjusts Price Target on Ascendis Pharma A/S to $163 From $157, Maintains Buy Rat..
MT
2022Credit Suisse Adjusts Ascendis Pharma's Price Target to $130 From $123, Keeps Outperform R..
MT
More recommendations
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 14
Last Close Price 108,79 €
Average target price 146,52 €
Spread / Average Target 34,7%
High Price Target 171,48 €
Spread / Highest target 57,6%
Low Price Target 88,26 €
Spread / Lowest Target -18,9%
Consensus detail
Consensus revision (last 18 months)